Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$15.35 -6.7%	$26.08	$14.72 ▼ $35.25	$1.52B	2.02	1.33 million shs	2.21 million shs
CBPO China Biologic Products	$119.99 +1.7%	$119.23	$99.74 ▼ $120.05	$4.72B	0.47	148,695 shs	24,016 shs
SWTX SpringWorks Therapeutics	$39.73 -7.8%	$48.65	$28.21 ▼ $62.00	$2.96B	0.79	1.33 million shs	1.96 million shs
VIR Vir Biotechnology	$5.57 -6.6%	$8.46	$5.49 ▼ $14.45	$765.94M	1.17	1.32 million shs	930,589 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-10.93%	-25.82%	-37.75%	-35.15%	-44.54%
CBPO China Biologic Products	0.00%	0.00%	0.00%	0.00%	0.00%
SWTX SpringWorks Therapeutics	-7.42%	-9.31%	-16.17%	+12.78%	-6.82%
VIR Vir Biotechnology	-8.02%	-10.64%	-27.32%	-20.53%	-38.49%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	3.0959 of 5 stars	4.5	1.0	0.0	0.0	3.0	2.5	0.6
CBPO China Biologic Products	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	1.8947 of 5 stars	3.5	2.0	0.0	0.0	2.3	0.8	0.6
VIR Vir Biotechnology	3.5078 of 5 stars	4.4	2.0	0.0	0.0	2.0	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$49.45	222.20% Upside
CBPO China Biologic Products	0.00	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	3.00	Buy	$73.20	84.24% Upside
VIR Vir Biotechnology	2.83	Moderate Buy	$35.67	540.57% Upside

Current Analyst Ratings Breakdown

Latest SWTX, BEAM, VIR, and CBPO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2025	BEAM Beam Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$42.00 ➝ $42.00
3/12/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/10/2025	BEAM Beam Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$34.00
3/10/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/10/2025	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$57.00
3/10/2025	BEAM Beam Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$40.00
3/3/2025	BEAM Beam Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$24.00 ➝ $25.00
2/28/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
2/28/2025	VIR Vir Biotechnology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $31.00
2/28/2025	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$110.00 ➝ $110.00
2/27/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$78.00 ➝ $78.00

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	24.11	N/A	N/A	$12.04 per share	1.27
CBPO China Biologic Products	$503.70M	9.38	$5.01 per share	23.93	$45.09 per share	2.66
SWTX SpringWorks Therapeutics	$191.59M	15.54	N/A	N/A	$10.01 per share	3.97
VIR Vir Biotechnology	$63.71M	11.99	N/A	N/A	$11.82 per share	0.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$132.53M	-$4.58	N/A	N/A	N/A	-41.07%	-16.22%	-10.94%	5/6/2025 (Estimated)
CBPO China Biologic Products	$138.81M	$4.28	33.52	27.90	N/A	27.43%	8.32%	7.64%	N/A
SWTX SpringWorks Therapeutics	-$325.10M	-$3.48	N/A	N/A	N/A	-134.73%	-46.74%	-41.12%	5/1/2025 (Estimated)
VIR Vir Biotechnology	-$615.06M	-$3.82	N/A	N/A	N/A	-678.40%	-36.71%	-31.00%	5/1/2025 (Estimated)

Latest SWTX, BEAM, VIR, and CBPO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	SWTX SpringWorks Therapeutics	-$0.79	N/A	N/A	N/A	$66.93 million	N/A
5/1/2025	N/A	VIR Vir Biotechnology	-$0.83	N/A	N/A	N/A	$8.59 million	N/A
2/26/2025	Q4 2024	VIR Vir Biotechnology	-$0.85	-$0.76	+$0.09	-$0.76	$8.14 million	$12.37 million
2/25/2025	Q4 2024	BEAM Beam Therapeutics	-$1.25	-$1.09	+$0.16	-$1.09	$16.47 million	$30.00 million
2/20/2025	Q4 2024	SWTX SpringWorks Therapeutics	-$0.66	-$1.04	-$0.38	-$1.04	$60.53 million	$61.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	5.86%	N/A	N/A	N/A
CBPO China Biologic Products	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	5.69	5.69
CBPO China Biologic Products	N/A	12.01	10.13
SWTX SpringWorks Therapeutics	N/A	6.16	6.02
VIR Vir Biotechnology	N/A	8.94	8.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CBPO China Biologic Products	34.77%
SWTX SpringWorks Therapeutics	N/A
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	4.20%
CBPO China Biologic Products	2.73%
SWTX SpringWorks Therapeutics	7.61%
VIR Vir Biotechnology	15.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	99.79 million	79.33 million	Optionable
CBPO China Biologic Products	2,269	39.36 million	N/A	Optionable
SWTX SpringWorks Therapeutics	230	74.94 million	68.73 million	Optionable
VIR Vir Biotechnology	580	137.14 million	116.24 million	Optionable

SWTX, BEAM, VIR, and CBPO Headlines

Recent News About These Companies

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of "Moderate Buy" by Analysts

April 3 at 2:09 AM | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low - Here's What Happened

April 2 at 4:11 AM | marketbeat.com

Stock Movers: Moderna, Tesla, Canada Goose

March 31, 2025 | bloomberg.com

WINTON GROUP Ltd Sells 38,730 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

March 31, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts

March 30, 2025 | marketbeat.com

Artisan Partners Limited Partnership Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)

March 30, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company

March 28, 2025 | finance.yahoo.com

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year Low - Time to Sell?

March 27, 2025 | marketbeat.com

49,651 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Fox Run Management L.L.C.

March 27, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Holdings Raised by Charles Schwab Investment Management Inc.

March 23, 2025 | marketbeat.com

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

March 21, 2025 | prnewswire.com

51,967 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Tejara Capital Ltd

March 19, 2025 | marketbeat.com

Bank of New York Mellon Corp Lowers Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

March 19, 2025 | marketbeat.com

Vir enrols first subject in Phase III programme to assess CHD therapy

March 14, 2025 | finance.yahoo.com

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

March 13, 2025 | pipelinereview.com

Vir Biotechnology enrolls first patient in ECLIPSE program

March 13, 2025 | markets.businessinsider.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund

March 5, 2025 | marketbeat.com

Hepatitis D Market to Expand Significantly by 2034, States DelveInsight Report | Gilead Sciences, Eiger BioPharma, Janssen R&D

March 4, 2025 | theglobeandmail.com

Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology

March 4, 2025 | seekingalpha.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts

March 4, 2025 | marketbeat.com

Barclays Remains a Buy on Vir Biotechnology (VIR)

February 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
Joby Aviation Stock: Virgin Atlantic Deal Signals Big Potential
By Jeffrey Neal Johnson | March 18, 2025
View Joby Aviation Stock: Virgin Atlantic Deal Signals Big Potential
Can SoundHound AI Double? What the Fundamentals and Deals Reveal
By Gabriel Osorio-Mazilli | March 25, 2025
View Can SoundHound AI Double? What the Fundamentals and Deals Reveal
Can TikTok Stock Picks Really Make You Rich?
By Dan Schmidt | March 17, 2025
View Can TikTok Stock Picks Really Make You Rich?

SWTX, BEAM, VIR, and CBPO Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$15.35 -1.11 (-6.75%)

As of 01:42 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

China Biologic Products NASDAQ:CBPO

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

SpringWorks Therapeutics NASDAQ:SWTX

$39.73 -3.34 (-7.75%)

As of 01:42 PM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Vir Biotechnology NASDAQ:VIR

$5.57 -0.39 (-6.58%)

As of 01:42 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time